"Biological Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
| Descriptor ID |
D001688
|
| MeSH Number(s) |
D20.215
|
| Concept/Terms |
Biological Products- Biological Products
- Biologic Products
- Products, Biologic
- Biologics
- Products, Biological
|
Below are MeSH descriptors whose meaning is more general than "Biological Products".
Below are MeSH descriptors whose meaning is more specific than "Biological Products".
This graph shows the total number of publications written about "Biological Products" by people in this website by year, and whether "Biological Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 3 | 0 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 5 | 1 | 6 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 6 | 0 | 6 |
| 2017 | 8 | 1 | 9 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 12 | 0 | 12 |
| 2021 | 9 | 4 | 13 |
| 2022 | 6 | 1 | 7 |
| 2023 | 8 | 0 | 8 |
| 2024 | 3 | 3 | 6 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Products" by people in Profiles.
-
Biologics in congenital ichthyosis: are they effective? Br J Dermatol. 2025 Jan 24; 192(2):327-334.
-
Perioperative Implications of Biologics and Immunotherapy. Adv Anesth. 2024 Dec; 42(1):97-113.
-
Anti-stroke biologics: from recombinant proteins to stem cells and organoids. Stroke Vasc Neurol. 2024 Nov 05; 9(5):467-480.
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
-
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. Expert Opin Biol Ther. 2024 Oct; 24(10):1005-1015.
-
Longitudinal Trends in Pregnancy Outcomes Among Women With Inflammatory Bowel Disease in the Era of Biologics: A 20-Year Nationwide Analysis. Inflamm Bowel Dis. 2024 10 03; 30(10):1788-1795.
-
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024 09 10; 8(17):4679-4688.
-
Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. Clin Rheumatol. 2024 Nov; 43(11):3301-3312.
-
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther. 2024 Nov; 30(11):1065-1079.
-
Biologics in Asthma: Emerging Biologics. Immunol Allergy Clin North Am. 2024 11; 44(4):751-763.